Lupin receives USFDA tentative approval for Dasatinib Tablets

2 Sep 2022 , 01:34 AM

Lupin in partnership with Pharmascience Inc today announced that it has received tentative approval from the United States Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA Dasatinib Tablets 20 mg 50 mg 70 mg 80 mg 100 mg and 140 mg to market a generic equivalent of Sprycel Tablets 20 mg 50 mg 70 mg 80 mg 100 mg and 140 mg of Bristol-Myers Squibb Company Dasatinib Tablets RLD Sprycel had estimated annual sales of USD 1569 million in the US IQVIA MAT June 2022